Literature DB >> 18197116

Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection.

Yanjie Yi1, Lamorris Loftin, Lingshu Wang, Sarah J Ratcliffe, Jesse Isaacman-Beck, Ronald G Collman.   

Abstract

Macrophages are important targets for HIV-1, and R5X4 strains play a central role in pathogenesis, especially in late-stage patients who may receive the fusion inhibitor T20 (enfuvirtide). Sensitivity to T20 varies markedly among HIV-1 strains and is influenced by viral and cellular factors that affect Env/CD4/coreceptor interactions. We addressed the relation between T20 inhibition and the pathway by which R5X4 HIV-1 infects primary macrophages, which express both coreceptors. In U87/CD4/coreceptor cells, T20 sensitivity for entry through CCR5 and CXCR4 was correlated. In macrophages, the proportion of total entry mediated by each coreceptor differed among isolates. Neither pathway was uniformly more or less sensitive to T20, however, nor did the proportion of entry mediated by each coreceptor predict T20 sensitivity. T20 sensitivity for macrophage infection overall correlated modestly with that for entry through CCR5 but not through CXCR4; however, unlike U87 cells, sensitivity of entry through CCR5 and CXCR4 was not correlated. These results suggest that strain-specific factors influence R5X4 T20 sensitivity regardless of the coreceptor used, an absence of systematic differences in efficiency by which R5X4 strains use the 2 coreceptors, and that efficiency and kinetics of interactions with CCR5 are central determinants of macrophage entry even when both pathways are utilized.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197116      PMCID: PMC2769518          DOI: 10.1097/QAI.0b013e31816520f6

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  29 in total

1.  Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.

Authors:  S Ghezzi; S Menzo; A Brambilla; P P Bordignon; A L Lorini; M Clementi; G Poli; E Vicenzi
Journal:  Virology       Date:  2001-02-15       Impact factor: 3.616

2.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

4.  HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process.

Authors:  S A Gallo; A Puri; R Blumenthal
Journal:  Biochemistry       Date:  2001-10-16       Impact factor: 3.162

Review 5.  Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands.

Authors:  G Simmons; J D Reeves; S Hibbitts; J T Stine; P W Gray; A E Proudfoot; P R Clapham
Journal:  Immunol Rev       Date:  2000-10       Impact factor: 12.988

6.  Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.

Authors:  Y Zhang; B Lou; R B Lal; A Gettie; P A Marx; J P Moore
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.

Authors:  Evelien H B Stalmeijer; Ronald P Van Rij; Brigitte Boeser-Nunnink; Janny A Visser; Marloes A Naarding; Dominique Schols; Hanneke Schuitemaker
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

Authors:  Ronald S Veazey; Per Johan Klasse; Thomas J Ketas; Jacqueline D Reeves; Michael Piatak; Kevin Kunstman; Shawn E Kuhmann; Preston A Marx; Jeffrey D Lifson; Jason Dufour; Megan Mefford; Ivona Pandrea; Steven M Wolinsky; Robert W Doms; Julie A DeMartino; Salvatore J Siciliano; Kathy Lyons; Martin S Springer; John P Moore
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

9.  Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages.

Authors:  Tatsuhiko Igarashi; Olivia K Donau; Hiromi Imamichi; Marie-Jeanne Dumaurier; Reza Sadjadpour; Ronald J Plishka; Alicia Buckler-White; Charles Buckler; Anthony F Suffredini; H Clifford Lane; John P Moore; Malcolm A Martin
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  An unusual syncytia-inducing human immunodeficiency virus type 1 primary isolate from the central nervous system that is restricted to CXCR4, replicates efficiently in macrophages, and induces neuronal apoptosis.

Authors:  Yanjie Yi; Wei Chen; Ian Frank; Joann Cutilli; Anjali Singh; Linda Starr-Spires; Jerrold Sulcove; Dennis L Kolson; Ronald G Collman
Journal:  J Neurovirol       Date:  2003-08       Impact factor: 2.643

View more
  7 in total

1.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.

Authors:  Ronald S Veazey; Thomas A Ketas; Per Johan Klasse; Donna K Davison; Morgan Singletary; Linda C Green; Michael L Greenberg; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-22       Impact factor: 11.205

3.  Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors.

Authors:  Louis Alexander; Sharon Zhang; Brian McAuliffe; David Connors; Nannon Zhou; Tao Wang; Michele Agler; John Kadow; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

Review 4.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

Review 5.  HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies.

Authors:  Paul R Gorry; Nicholas Francella; Sharon R Lewin; Ronald G Collman
Journal:  J Leukoc Biol       Date:  2013-10-24       Impact factor: 4.962

Review 6.  R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies.

Authors:  Lamorris M Loftin; Martha Kienzle; Yanjie Yi; Ronald G Collman
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

Review 7.  The macrophage: a therapeutic target in HIV-1 infection.

Authors:  Amit Kumar; Georges Herbein
Journal:  Mol Cell Ther       Date:  2014-04-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.